Famciclovir Tablet 250 Milligrams (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer famciclovir 250 mg per dose orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of initial genital herpes infection Adults: Administer this drug 250 mg per dose orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes infection Adults: Administer this drug 125 mg per dose orally twice daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer this drug 250 mg per dose orally twice daily. Periodically interrupt treatment every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Since the clearance of this drug is reduced in patients with renal impairment, adjust the dose with caution. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose twice daily 10～29 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 125 mg per dose twice daily 10～29 125 mg per dose once daily 3) Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) Dose 30～59 250 mg per dose twice daily 10～29 125 mg per dose twice daily 4) If only serum creatinine is known, creatinine clearance may be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients undergoing hemodialysis, it is preferable to administer the drug every 48 hours, taking the dialysis interval into account. A 4-hour hemodialysis session reduces the plasma concentration of this drug by approximately 75%; therefore, administer this drug immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, a clear recommended dose has not been established.

This medication should not be administered to certain patients. Patients who are allergic to this medication or its components should not use it. Additionally, since it contains lactose, patients with lactose intolerance or related genetic disorders should also avoid using it. Patients with allergies to soybean oil, soy, or peanuts should also avoid this medication. Patients with poor kidney function or abnormalities in fat metabolism should use this medication cautiously. Specifically, patients with hyperlipidemia, diabetic dyslipidemia, or pancreatitis require attention. The use of this medication may result in side effects such as headaches, nausea, vomiting, dizziness, skin rashes, and itching. Rarely, severe side effects such as thrombocytopenia, hallucinations, palpitations, liver function abnormalities, and acute renal failure may occur. Therefore, if abnormal symptoms arise, it is essential to consult healthcare professionals immediately. This medication does not cure genital herpes, and if symptoms persist during treatment, sexual contact should be avoided, and safe sexual practices should be maintained. It is advisable not to drive or operate machinery if dizziness or drowsiness occurs. Patients with mild or moderate liver function impairment do not require dose adjustments; however, in severe liver impairment, the effectiveness of this medication may diminish. Patients at risk of fat overload should regularly check blood lipid levels and adjust medication dosages accordingly. This medication has a low potential for interactions with other drugs; however, care is needed if taken with medications like probenecid, as it may increase blood concentration levels. Close monitoring of therapeutic effects is required when used in conjunction with lamoxifen. Women who are pregnant or may become pregnant should carefully consider the benefits and risks of treatment, and the same applies to nursing mothers. The safety and efficacy of this medication in pediatric patients under 18 years have not been established, and its use is not recommended. Generally, elderly patients do not require dosage adjustments; however, those with impaired kidney function should have their doses adjusted appropriately. In the case of overdose, appropriate supportive and symptomatic treatment is necessary, and blood dialysis may reduce the concentration of the medication. This medication should be stored in a dry place below 30 degrees Celsius, securely out of reach of children. Care should be taken not to transfer it to other containers, as this may jeopardize quality.

• Headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication must be stored in a tightly sealed container to prevent exposure to air and moisture. Furthermore, it is advisable to store it in a dry place away from direct sunlight and below 30 degrees Celsius.

Appearance

White round film-coated tablet

Package unit

21 tablets/box [(7 tablets/PTP X 3)]